Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ON012380

Known as: ON 012380, ON-012380 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells 
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Proliferation centers in chronic lymphocytic leukemia: the niche where NF-κB activation takes place 
  • figure 3
  • table 1
Is this relevant?
2009
2009
Abstract : Because it is now apparent that a significant proportion of patients chronically treated with imatinib develop… Expand
  • table 1
  • figure 1
Is this relevant?
Review
2006
Review
2006
Imatinib mesylate, Abl tyrosine kinase inhibitor, has improved the treatment of Bcr-Abl-positive leukemia such as chronic myeloid… Expand
Is this relevant?
Review
2006
Review
2006
Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia… Expand
Is this relevant?
Review
2006
Review
2006
Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that specifically inhibits the BCR-ABL… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Imatinib, which is an inhibitor of the BCR-ABL tyrosine kinase, has been a remarkable success for the treatment of Philadelphia… Expand
  • figure 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?